Compare IDEXX Laboratories, Inc. (IDXX) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Peloton Interactive Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Peloton Interactive Inc trades at $5.6 (market cap $2.46B). The key difference: IDEXX Laboratories, Inc. is far larger — about 18.8× Peloton Interactive Inc's market cap, and Peloton Interactive Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | PTON | |
|---|---|---|
Market Cap | $46.22B | $2.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $9.00 |
52-Week Low | $526.44 | $3.71 |
Enterprise Value | $47.12B | $2.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Peloton Interactive (PTON) trades at $5.42, down 1.63% today, with a bearish technical signal and negative shareholder equity. The company achieved its first annual net profit in fiscal 2026, with Q4 earnings beating estimates at $0.13 per share. Revenue declined to $2.49 billion in 2025, but net losses narrowed significantly to $119 million. Cash flow turned positive at $335 million, and debt-to-asset ratio improved to 63.18% in 2026. Analyst sentiment is mixed with a 50% buy rating.
Outlook remains cautious due to ongoing revenue declines and high debt, but profitability improvements and cost controls provide a foundation for recovery. Key risks include subscriber losses, competitive pressures, and patent litigation. The stock offers speculative upside if growth stabilizes, but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
